Biomarker guidance in selection among breakthrough treatment options in advanced and recurrent endometrial cancer.

Chan JK, Tewari K, Monk BJ, Herzog TJ, Coleman RL, Richardson MT, Kapp DS, Francoeur AA.

DOI: 10.1016/j.ygyno.2024.05.022
Published: 2024-06-04
Container: Gynecol Oncol
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ygyno.2024.05.022,
  title = {Biomarker guidance in selection among breakthrough treatment options in advanced and recurrent endometrial cancer.},
  author = {Chan JK and  Tewari K and  Monk BJ and  Herzog TJ and  Coleman RL and  Richardson MT and  Kapp DS and  Francoeur AA.},
  year = {2024},
  journal = {Gynecol Oncol},
  doi = {10.1016/j.ygyno.2024.05.022},
  url = {https://doi.org/10.1016/j.ygyno.2024.05.022}
}

RIS

TY  - JOUR
TI  - Biomarker guidance in selection among breakthrough treatment options in advanced and recurrent endometrial cancer.
AU  - Chan JK
AU  -  Tewari K
AU  -  Monk BJ
AU  -  Herzog TJ
AU  -  Coleman RL
AU  -  Richardson MT
AU  -  Kapp DS
AU  -  Francoeur AA.
PY  - 2024
JO  - Gynecol Oncol
DO  - 10.1016/j.ygyno.2024.05.022
UR  - https://doi.org/10.1016/j.ygyno.2024.05.022
ER  -

APA

JK, C., K, T., BJ, M., TJ, H., RL, C., MT, R., DS, K., & AA., F. (2024). Biomarker guidance in selection among breakthrough treatment options in advanced and recurrent endometrial cancer.. Gynecol Oncol. https://doi.org/10.1016/j.ygyno.2024.05.022

Source records

europe-pmc · retrieved 2026-09-27T07:34:22.511Z